We are live on
!
Find out more
Primecap Management Portfolio holdings
AUM
$127B
1-Year Est. Return
44.11%
This Fund
S&P 500
This Quarter
Est. Return
+10.56%
1 Year Est. Return
+44.11%
3 Year Est. Return
+121.64%
5 Year Est. Return
+154.22%
10 Year Est. Return
+724.54%
AUM
$120B
AUM Growth
+$5B
(+4.4%)
Cap. Flow
-$4.23B
Cap. Flow
% of AUM
-3.53%
Top 10 Holdings %
Top 10 Hldgs %
33.52%
Holding
335
New
4
Increased
58
Reduced
216
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$227M |
| 2 |
GSK
GSK
|
+$68.2M |
| 3 |
Elanco Animal Health
ELAN
|
+$48.2M |
| 4 |
Intel
INTC
|
+$45M |
| 5 |
Capri Holdings
CPRI
|
+$44.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$764M |
| 2 |
Microsoft
MSFT
|
+$272M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$262M |
| 4 |
Caterpillar
CAT
|
+$148M |
| 5 |
Novartis
NVS
|
+$142M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.41% |
| 2 | Technology | 30.05% |
| 3 | Industrials | 12.22% |
| 4 | Consumer Discretionary | 9.43% |
| 5 | Financials | 7.23% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Eli Lilly
LLY
$1.07T
| $11B | 9.23% |
23,546,201
-1,821,349
| -7% | -$764M |
|
2
Biogen
BIIB
$29.9B
| $4.56B | 3.81% |
16,025,876
+24,710
| +0.2% | +$7.36M |
|
|
3
Microsoft
MSFT
$2.84T
| $3.6B | 3.01% |
10,574,687
-866,371
| -8% | -$272M |
|
4
Amgen
AMGN
$203B
| $3.27B | 2.73% |
14,736,435
-376,268
| -2% | -$87.3M |
|
5
FedEx
FDX
$74.5B
| $3.27B | 2.73% |
13,182,907
-385,985
| -3% | -$88.3M |
|
6
AstraZeneca
AZN
$263B
| $3.15B | 2.64% |
22,038,650
-656,279
| -3% | -$96.6M |
|
7
Adobe
ADBE
$89.5B
| $2.99B | 2.5% |
6,108,578
-184,575
| -3% | -$74.4M |
|
8
KLA
KLAC
$275B
| $2.95B | 2.47% |
60,878,990
-2,619,900
| -4% | -$109M |
|
9
Texas Instruments
TXN
$255B
| $2.87B | 2.4% |
15,928,105
-716,340
| -4% | -$123M |
|
10
Tesla
TSLA
$1.24T
| $2.41B | 2.01% |
9,204,430
-674,470
| -7% | -$135M |
|
11
Micron Technology
MU
$1.04T
| $2.4B | 2% |
38,014,731
-935,206
| -2% | -$60.1M |
|
|
12
Intel
INTC
$466B
| $2.36B | 1.97% |
70,535,501
+1,432,330
| +2% | +$45M |
|
13
Alphabet (Google) Class A
GOOGL
$3.91T
| $2.35B | 1.96% |
19,619,805
-1,161,940
| -6% | -$134M |
|
14
Sony
SONY
$123B
| $2.06B | 1.72% |
114,362,065
-5,762,725
| -5% | -$108M |
|
15
Boston Scientific
BSX
$65.8B
| $2.02B | 1.69% |
37,428,979
-899,250
| -2% | -$47M |
|
16
Wells Fargo
WFC
$261B
| $1.9B | 1.58% |
44,404,555
-2,974,395
| -6% | -$120M |
|
17
Southwest Airlines
LUV
$22.1B
| $1.81B | 1.51% |
50,050,662
-801,967
| -2% | -$25.1M |
|
|
18
Thermo Fisher Scientific
TMO
$211B
| $1.61B | 1.34% |
3,078,107
-486,002
| -14% | -$262M |
|
19
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.59B | 1.33% |
18,383,619
+140,190
| +0.8% | +$13.2M |
|
|
20
Alphabet (Google) Class C
GOOG
$3.9T
| $1.58B | 1.32% |
13,039,525
-705,460
| -5% | -$81.7M |
|
21
Oracle
ORCL
$331B
| $1.57B | 1.32% |
13,225,091
-759,900
| -5% | -$78.6M |
|
|
22
Novartis
NVS
$295B
| $1.51B | 1.27% |
15,010,675
-1,416,360
| -9% | -$142M |
|
23
Alibaba
BABA
$269B
| $1.45B | 1.21% |
17,352,479
+69,202
| +0.4% | +$6.06M |
|
24
Bristol-Myers Squibb
BMY
$127B
| $1.34B | 1.12% |
20,947,045
-567,360
| -3% | -$38M |
|
25
Raymond James Financial
RJF
$32.5B
| $1.32B | 1.1% |
12,701,532
-135,025
| -1% | -$12.5M |
|
Similar funds
Primecap Management's Q2 2023 Portfolio in Review
As of Q2 2023, Primecap Management held 335 positions worth $120B, up 4.4% from $115B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Primecap Management withdrew a net $4.23B in Q2 2023, closing 7 positions and reducing 216 holdings. Its most notable exit was Maxar Technologies Inc. Common Stock, an estimated $27M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Technology and Industrials.
Against the trend, Primecap Management opened a new position in Sphere Entertainment worth $17.1M.
- Primecap Management's largest Q2 2023 buy was Sphere Entertainment: 623,078 shares worth $17.1M.
- Primecap Management added most to Seagen Inc. Common Stock in Q2 2023, an estimated $227M increase.
- Primecap Management's biggest Q2 2023 reduction was Eli Lilly, cutting an estimated $764M.
- Primecap Management fully exited Maxar Technologies Inc. Common Stock in Q2 2023, selling an estimated $27M.
- Primecap Management's ten largest holdings make up 34% of its $120B portfolio in Q2 2023.
- Primecap Management opened 4 new positions and closed 7 in Q2 2023.
- Primecap Management's portfolio value rose 4.4% quarter-over-quarter to $120B.
Based on Primecap Management's 13F filing for Q2 2023, filed 11 Aug 2023.